Latest News

Starpharma to present at OTCQX Virtual Investor Conference

Jun 18th, 2020

Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 18 June 2020 (US ET) as part of OTCQX’s Virtual Investor Conference for Global Mid-cap and Large-cap Companies. The conference is primarily attended  by US-based  retail investors, as well as advisors.


Read More

DEP® lutetium effective in human prostate cancer model

Jun 17th, 2020

Starpharma today announced results from its first radiotherapeutic candidate, DEP® lutetium. DEP® lutetium is a patented nanoparticle which incorporates the radioisotope Lutetium-177 on a DEP® dendrimer scaffold. 


Read More

VivaGel® BV launched in central and eastern European countries

Jun 16th, 2020

Starpharma today announced that VivaGel® BV has been launched in Central and Eastern European (CEE) region. This launch follows European launches in Germany, UK and several other European countries.

Read More

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan 

>> DEP® patient case studies

>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received

>> New DEP® ADC programs

>> DEP® pipeline targets multiple high-value areas

>> Other DEP® programs

>> Outlook, recent news & events


Read More

In the media

Starpharma collects milestone payment from AstraZeneca

Feb 13th, 2020

Biotech Dispatch reported that AstraZeneca has paid Starpharma a $4.5 million milestone payment following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466. The article mentioned the long standing partnership between the two companies which is focused on using Starpharma’s DEP® drug delivery platform to enhance AstraZeneca’s medicines.

To read the full article click here

Read More

Starpharma share price charges higher on product launch news

Feb 13th, 2020

The Motley Fool reported a rise in Starpharma’s share price off the back of the announcement that its VivaGel® BV product will be launched in Asia by Mundipharma. The article highlighted that the deal is an important commercial opportunity for Starpharma with the product set to be accessible to more than 1.5 billion women.

To read the full article, click here

Read More

Starpharma tech ready to deliver

Nov 11th, 2019

The Austraian published an interview with Starpharma CEO Dr Jackie Fairley where she discussed the potential of the dendrimer technology, how it is applied to cancer drugs and the potential benefits it provides to patients.

To read the full article, click here. (paywall)

Read More

Dendrimer drug delivery enhances chemotherapy gemcitabine in human pancreatic mode

Nov 1st, 2019

Online pharmaceutical publication Pharma in Focus noted Starpharma’s positive DEP® gemcitabine results in a human pancreatic model, noting it was one of multiple DEP® drugs from the company.

To read the full article, click here.

Read More

Shareholder Updates

Shareholder Update January 2019

Jan 17th, 2019

In this issue: 

>> FDA requests further data for VivaGel® BV approval in the US

>> Launch of VivaGel® BV in multiple territories

>> VivaGel® BV licensed to ITF Pharma in the US

>> VivaGel® condom approved in Japan

>> Clinical trials for internal DEP® products progressing well

>> Patent published for AstraZeneca-DEP® drugs: DEP® Bcl2/xL inhibitors show compelling efficacy & synergy in combination

>> DEP® docetaxel & DEP® cabazitaxel outperformed both gemcitabine & Abraxane®

>> SPL7013 eye drops for viral conjunctivitis

>> Partnering activities 

>> Macquarie initiates coverage of Starpharma

>> Outlook

 Download: Shareholder Update January 2019 (pdf file, 557kb)


Read More

Shareholder Update February 2018

Feb 19th, 2018

In this issue: 

>> New sites open for the DEP® docetaxel phase 2 trial

>> DEP® cabazitaxel phase 1 / 2 trial commences

>> VivaGel® BV NDA submission lodged under Fast Track program

>> VivaGel® BV approved by TGA

>> DEP® irinotecan progressing towards the clinic

>> AstraZeneca-Starpharma collaboration

>> Extensive global licensing negotiations for VivaGel® BV

>> Positive market research findings for VivaGel® BV 

>> Q2 Cashflow Report at 31 December 2017

>> OTCQX market recognition

>> Starpharma News & Events

>> Outlook

 Download: Shareholder Update February 2018 (pdf file, 1.5mb)

Read More

Sign up to receive news here